New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 18, 2014
10:01 EDTCSGP, TSQ, TKMR, SYRG, SBLK, SMI, SEAS, PFNX, MVNR, MELA, XENT, IMDZ, STAY, EPAM, DSGX, CTSO, VTSSOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: CoStar Group (CSGP) initiated with a Buy at Goldman... CytoSorbents (CTSO) initiated with a Buy at H.C. Wainwright... Descartes Systems (DSGX) initiated with an Overweight at Barclays... EPAM Systems (EPAM) initiated with a Sell at Monness Crespi... Extended Stay America (STAY) resumed with an Overweight at JPMorgan... Immune Design (IMDZ) initiated with a Buy at Jefferies... Intersect ENT (XENT) initiated with an Outperform at Leerink... MELA Sciences (MELA) initiated with a Buy at H.C. Wainwright... Mavenir Systems (MVNR) coverage resumed with a Buy at BofA/Merrill... Pfenex (PFNX) initiated with a Buy at Mizuho... SeaWorld (SEAS) initiated with an Outperform at Credit Suisse... Semiconductor Manufacturing (SMI) initiated with an Overweight at Barclays... Star Bulk Carriers (SBLK) initiated with an Overweight at Evercore... Synergy Resources (SYRG) initiated with a Buy at Canaccord... Tekmira (TKMR) initiated with an Outperform at Leerink... Townsquare Media (TSQ) initiated with a Buy at BofA/Merrill... Vitesse (VTSS) initiated with an Outperform at Northland.
News For CSGP;CTSO;DSGX;EPAM;STAY;IMDZ;XENT;MELA;MVNR;PFNX;SEAS;SMI;SBLK;SYRG;TKMR;TSQ;VTSS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 14, 2014
09:04 EDTTKMRChinese company says drug can cure Ebola, Reuters reports
Subscribe for More Information
05:40 EDTTKMRTekmira partner Alnylam reports positive clinical data for Patisiran study
Tekmira Pharmaceuticals (TKMR) reported that Alnylam Pharmaceuticals (ALNY) presented six-month clinical data for the ongoing Patisiran Phase II Open Label Extension, or OLE, study in patients with Familial Amyloidotic Polyneuropathy, or FAP. Patisiran is an RNAi therapeutic targeting transthyretin, or TTR, in development for the treatment of TTR-mediated amyloidosis, or ATTR, which is enabled by Tekmira's lipid nanoparticle, or LNP, technology. Alnylam presented data at the American Neurological Association's 2014 Annual Meeting. Results showed a mean 0.95 point decrease in modified Neuropathy Impairment Score at six months in 19 patients with mNIS+7 data available for the current analysis. This decrease in neuropathy progression compares favorably with the 7 to 10 point increase in mNIS+7 at six months that can be estimated from historical data sets in untreated FAP patients with similar baseline characteristics.
October 13, 2014
11:12 EDTSBLKStar Bulk Carriers management to meet with Jefferies
Subscribe for More Information
07:12 EDTTKMROligonucleotide Therapeutics Society to hold annual meeting
Subscribe for More Information
07:11 EDTTKMRTekmira volatility elevated, Texas health-care worker tests positive for Ebola
Subscribe for More Information
October 12, 2014
19:26 EDTTKMRPatient being evaluated at Boston hospital for possible Ebola, Boston Globe says
Health officials say that a man that recently traveled to Liberia is being assessed at Beth Israel Deaconess hospital in Boston for the Ebola virus, the Boston Globe says. Drug companies that are working on experimental Ebola treatments include Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Reference Link
19:12 EDTTKMRCDC confirms Texas healthcare worker positive for Ebola
Subscribe for More Information
14:18 EDTTKMRNY's JFK Airport begins Ebola screenings, WSJ says
Subscribe for More Information
12:48 EDTTKMRTexas health-care worker tests positive for Ebola, WSJ says
Subscribe for More Information
October 10, 2014
10:54 EDTTKMRMapp looking to up production of experimental Ebola treatment, WSJ says
Mapp Biopharmaceutical is aiming to broaden the manufacturing of its experimental Ebola treatment, ZMapp, according to The Wall Street Journal, citing comments from the company. Mapp said that the treatment was given to a few infected individuals prior to supplies running out two months ago. Drug companies that are working on experimental Ebola treatments include Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Reference Link
October 9, 2014
17:01 EDTPFNXPfenex, PATH partner on vaccines
Subscribe for More Information
14:55 EDTTKMRHospital says deputy showing no signs of Ebola, AP reports
Subscribe for More Information
14:24 EDTTKMRCDC head compares Ebola to AIDS, Washington Post says
Subscribe for More Information
14:13 EDTTKMRFirst Ebola vaccine trial in West Africa started, NBC News reports
Subscribe for More Information
12:06 EDTTKMRLakeland Industries continues surge amid Ebola fears
Subscribe for More Information
05:50 EDTTKMRStocks with implied volatility movement; ARWR TKMR
Stocks with implied volatility movement; Arrowhead (ARWR) 158, Tekmira (TKMR) 130 according to iVolatility.
October 8, 2014
17:10 EDTXENTIntersect ENT announces publication of data from three studies
Subscribe for More Information
11:59 EDTTKMRTekmira volatility increases after Ebola patient dies
Subscribe for More Information
11:22 EDTTKMRChimerix falls after Ebola patient taking experimental drug dies
Shares of Chimerix (CMRX) are moving lower after the Texas Health Presbyterian Hospital Dallas announced that Thomas Eric Duncan succumbed to Ebola. Duncan was being treated with Chimerix's experimental drug Brincidofovir. Shares of Chimerix dropped 9% following the news to $30.19. Other makers of experimental Ebola treatments include Tekmira (TKMR), Sarepta (SRPT) and BioCryst (BCRX).
06:22 EDTSBLKStar Bulk Carriers coverage assumed with a Buy at Maxim
Target $17.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use